两种消融技术治疗放疗后复发前列腺癌的长期结局
研究比较了放疗后复发前列腺癌患者接受补救性冷冻治疗(sCT)与高强度聚焦超声(sHIFU)的长期肿瘤学结局。共纳入187例sCT和113例sHIFU患者,中位随访116个月。sHIFU与更高的生化复发和去势抵抗风险相关,但两种治疗的前列腺癌特异性死亡率无差异。
要点
- sHIFU较sCT与更高的生化复发风险相关(HR 1.65)。
- sHIFU较sCT与更高的去势抵抗风险相关(HR 2.31)。
- 两种治疗的前列腺癌特异性死亡率无差异。
核心结论
- sHIFU的生化复发和去势抵抗风险高于sCT,但前列腺癌特异性死亡率无差异。
研究设计与样本
- 回顾性队列研究,纳入1995-2004年接受sCT的187例和2006-2018年接受sHIFU的113例患者。
- 采用竞争风险生存分析和Fine and Gray回归进行多变量分析。
主要发现
- 170例(57.6%)出现生化复发,68例(23.4%)发生转移,143例(49.3%)开始ADT,58例(20.1%)出现去势抵抗。
- 162例死亡,其中59例(36.4%)死于前列腺癌。
- 多变量分析显示sHIFU与生化复发风险升高相关(HR 1.65,95%CI 1.15-2.36,p=0.006)。
- sHIFU与去势抵抗风险升高相关(HR 2.31,95%CI 1.23-4.35,p=0.009)。
- 补救前PSA与生化复发风险升高相关(HR 1.09,95%CI 1.06-1.13,p<0.0001)。
关键数值与推荐
- 前列腺癌特异性死亡的10年累积发生率为16.5%(95%CI 12.2-21.4%),20年为28.4%(95%CI 22.1-34.9%),两种治疗间无差异。
- 补救前PSA是所测肿瘤学结局的共同预测因素。
临床怎么用
- 对于放疗后复发的前列腺癌患者,sCT和sHIFU均可作为补救性全腺消融选项。
- sHIFU术后需更关注生化复发和去势抵抗的风险监测。
- 长期随访显示约50%的患者在10年后开始ADT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In men with recurrence of prostate cancer post radiation therapy, further treatment remains a challenge. The default salvage option of androgen-deprivation therapy (ADT) has adverse effects. Alternatively, selected men may be offered salvage therapy to the prostate. Herein, we present long-term oncological outcomes of two whole-gland ablation techniques, cryotherapy (sCT) and high-intensity-focused ultrasound (sHIFU). METHODS: Men undergoing sCT (1995-2004) and sHIFU (2006-2018) at Western University were identified. Oncological endpoints included biochemical recurrence (BCR), ADT initiation, metastases, castration resistance (CRPC), and prostate cancer-specific mortality (PCSM). Survival analysis with competing risks of mortality was performed. Multivariable analysis was performed using Fine and Gray regression. RESULTS: A total of 187 men underwent sCT and 113 sHIFU. Mean (SD) age of the entire cohort was 69.9 (5.9 years), median pre-radiation PSA 9.6 ng/ml (IQR 6.1-15.2), and pre-salvage PSA 4.5 ng/ml (IQR 2.8-7.0). Median total follow-up was 116 months (IQR 67.5-173.8). A total of 170 (57.6%) developed BCR, 68 (23.4%) metastases, 143 (49.3%) were started on ADT, 58 (20.1%) developed CRPC, and 162 (56%) patients died of which 59 (36.4%) were of prostate cancer. On multivariable analysis, sHIFU (HR 1.65, 95% CI 1.15-2.36, p = 0.006) and pre-salvage PSA (HR 1.09, 95% CI 1.06-1.13, p < 0.0001) were associated with a higher risk of BCR. Similarly, sHIFU patients had a higher risk of CRPC (HR 2.31, 95% CI 1.23-4.35, p = 0.009). The cumulative incidence (for both treatments) of PCSM was 16.5% (95% CI 12.2-21.4%) at 10 years and 28.4% (95% CI 22.1-34.9%) at 20 years, with no difference between treatment modalities. Pre-salvage PSA was a common predictor for the measured oncological outcomes. CONCLUSIONS: Although sHIFU had higher BCR and CRPC rates, there were no differences in PCSM when compared with sCT. The long-term oncological data on two ablation techniques highlighted that only 50% of patients started ADT after 10-year follow-up.
引用
- Nair SM, Peters M, Kurver P, et al. Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 32814843. doi:10.1038/s41391-020-00265-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。